Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 8, 2008

Cenomed Licenses TorreyPines' Compounds for Chemical Defense Settings

  • Cenomed BioSciences has acquired rights to three compounds from TorreyPines Therapeutics for chemical defense and counterterrorism defense: phenserine, Posiphen™, and bisnorcymcerine. TorreyPines will receive milestone and royalty payments.

    The company plans to prepare these compounds to prevent toxicity following exposure to chemical organophosphorus nerve agents including the chemical warfare agents sarin, soman, tabun, and VX. The candidates have the potential to restore inactivated muscle cells and neural cells throughout the body, according to the companies.

    Phenserine and Posiphen have reportedly been proven safe and well tolerated following oral administration in clinical trials, while bisnorcymcerine has completed preclinical evaluation.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »